Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 1.00 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | HAO2 | Q9NYQ3 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701592 | 0.83 | HCAR2 (0.70) | HCAR2DAO | |
| SCHEMBL30300433 | 0.81 | HCAR2 (0.68) | HCAR2DAO | |
| SCHEMBL17766421 | 0.78 | HCAR2 (0.63) | HCAR2 | |
| SCHEMBL30300526 | 0.78 | HCAR2 (0.63) | HCAR2KMT2A | |
| SCHEMBL4631308 | 0.77 | HCAR2 (0.63) | HCAR2DAOHAO2 | |
| SCHEMBL2763438 | 0.77 | HCAR2 (0.63) | HCAR2KMT2A | |
| SCHEMBL27575758 | 0.76 | HCAR2 (0.61) | HCAR2DAOHAO2 | |
| SCHEMBL2846088 | 0.75 | HCAR2 (0.59) | HCAR2KMT2A | |
| SCHEMBL24423821 | 0.74 | HCAR2 (0.59) | HCAR2KMT2A | |
| SCHEMBL2543083 | 0.74 | HCAR2 (0.59) | HCAR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | claimed |
| EP-3867248-B1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-12-10 | — | — | EP | disclosed |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2023-03-07 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| WO-2013059666-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| EP-2451450-A1 | NEW INHIBITORS OF PROLINE RACEMASE ENZYMES | Institut Pasteur (FR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004323-A1 | NEW INHIBITORS OF PROLINE RACEMASE ENZYMES | INSTITUT PASTEUR (FR) | 2011-01-13 | — | — | WO | disclosed |
| EP-2272510-A1 | Inhibitors of the proline racemase of trypanosoma cruzi | Institut Pasteur (FR) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009123714-A2 | PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | HCAR2 3796/4885DAO 3174/4885HAO2 4477/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | HCAR2 308/4885DAO 1554/4885HAO2 2372/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | HCAR2 3796/4885DAO 3174/4885HAO2 4477/4885 |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC3 | HCAR2 3821/4885DAO 3240/4885HAO2 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.